Intracellular ROS protection efficiency and free radical-scavenging activity of curcumin
A proof-of-concept, open-label trial of weekly exenatide (2 mg, 48 weeks, 50 patients) showed an advantage in the unified multiple system atrophy rating scale (UMSARS, parts I and II combined score) at 48 weeks compared with best medically treated participants, but no difference in more objective secondary measures or biomarkers (neurofilament light chain [NfL], CSF -synuclein oligomers) (165)
Moreover, the average value of tiredness decreased by 0.49 (mean=0.49) after three months of medication with L-carnitine and continued to drop after six months of medication (mean=0.88)
Some of these protective and healing effects are possible by BPC 157's ability to redirect blood circulation and provide the necessary support to the damaged area after damage (5)
Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, Whitton P, Wyse R, Isaacs T, Lees A, et al